Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...
CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.
Phase 3 trial results suggest daratumumab, which is approved for multiple myeloma, may also be effective at reducing relapse risk in neuromyelitis optica spectrum disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results